Sanofi-Synthelado

SL77.0499-10  (ALFUZOSIN)

Bibliography

 

 

 

1.     Malik M.  Problems of heart rate correction in assessment of drug-induced QT interval prolongation.  J Cardiovasc Electrophysiol 2001; 12:411-20.

 

2.     Hnatkova K, Malik M.  "Optimum" formulae for heart rate correction of the QT interval.  PACE 1999; 22:1683-7.

 

3.     Badilini F, Maison-Blanche P, Childers R, Coumel P.  QT interval analysis on ambulatory ECG recordings: a selective beat averaging approach.  Med Biol Eng Comput 1998; 36:1-10.

 

4.     Extramiana F, Maison-Blanche P, Badilini F, Pinoteau J, Deseo T, Coumel P. Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences.  J Electrocardiol 1999; 32:33-43.

 

5.     Preliminary concept paper:  The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.  Revised version 6 February 2003.

 

6.     USFDA: summary basis of approval to NDA 21-085, sup 10 for moxifloxacin - Approved 27 April 2001. (Not provided).

 

7.     Rhodes PR, Krogh RH, Bruskewitz RC.  Impact of drug therapy on benign prostatic hyperplasia-specific quality of life.  Urology 1999; 53:1090-8.

 

8.     Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337:1457-61.

 

9.     Teillac P, Delauche-Cavallier MC, Attali P, et al. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin, Br J Urol 1992; 70:58-64.

 

10.  Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. Br J Urol 1993; 72:615-20.

 

11.  Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. Br J Urol 1993; 74:579-84.

 

12.  Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, et al.  Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31:190-8.

 

13.  Debruyne FMJ, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34:169-75.

 

14.  McNeill SA, Daruwala PD, Mitchell IDC, et al. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo‑controlled trial. BJU Int 1999; 84:622-7.

 

15.  Physicians's Desk Reference 2003, Hytrin Monographs.

 

16.  Physicians's Desk Reference 2003, Cardura.

 

17.  Physicians's Desk Reference 2003, Flomax.

 

18.  Funck-Brentano C, Jaillon P. Rate-corrected QT interval: Techniques and limitations. Am J Cardiol 1993;72:17B-22B.

 

19.  Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.  Eur Heart J 2000; 21:1216-31.

 

20.  Malik M, Camm AJ.  Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labelling.  Drug Safety 2001; 24(5):323-51.

 

21.  Malik M.  The imprecision heart rate correction may lead to artificial observations of drug induced QT interval changes.  PACE 2002; 25(2):209-16.

 

22.  Aytemir K, Maarouf N, Gallagher MM, Yap YG, Waktare JEP, Malik M.

a.      Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms.  PACE  1999; 22:1397-1401.

 

23.  Bonate PL, Russell T. Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective.  J Clin Pharmacol 1999; 39:349-58.

 

24.  NDA 20-919: Zeldox (ziprasidone mesylate IM, Pfizer.) Briefing information. Pfizer. 15 Feb 2001 http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2.htm. (Not provided).

 

25.  Ketek (telithromycine) Briefing Information, Aventis. 26 April 2001 http://www.fda.gov/ohrms/dockets/ac/01/briefing/3746b1.htm. (Not provided).

 

26.  Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.  Heart 2002; 87:220-8.

 

27.  Moss AJ, Zareba W, Benhorin J, Couderc JP, Kennedy H, Locati‑Heilbron E, Maison‑Blanche P. ISHNE guidelines for electrocardiographic evaluation of drug‑related QT prolongation and other alterations in ventricular repolarization: task force summary.  A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. ANE 2001; 6(4):333-41.

 

28.  Goodman DB.

a.      Continuous 12-lead ECG recording.  Analysis of digital ECG data.  What can you do with the digitized ECG waveform that you cannot do with a paper ECG record?

b.     Public presentation at FDA ECG data standards meeting (November 2001)

 

29.  http://www.fda.gov/cder/regulatory/ersr/Goodman[1].ppt

 

30.  Molnar J, Weiss J, Zhang F, Rosenthal JE.  Evaluation of five QT correction formulas using a software-assisted method of continuous QT measurement from 24-hour Holter recordings.  Am J Cardiol 1996; 78:920-6.

 

31.  Lepeschkin E, Surawicz B.  The measurement of the Q-T interval of the electrocardiogram.  Circulation 1952; 6:378-88.

 

32.  Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE Gilman AG, editors. Goodman & Gilman's  The pharmacological basis of therapeutics, 10th ed.  New York: McGraw‑Hill; 2001.  p.215-68.

 

33.  Stinson JC, Pears JS, Williams AJ, Campbell RWF.  Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers.  Br J Clin Pharmacol 1995; 39:651-6.

 

34.  Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C.  Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.  Eur Urol 1996; 29: 29-35.

 

35.  Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54:188-202.